On this week’s episode of Industry Focus: Financials host Jason Moser sits down with Kevin Bennett, CEO of MotoRefi, a company focused on helping consumers save through refinancing their vehicle. Then listen in as Jason wraps up with a few thoughts on how investors can handle crazy news cycles.
Earnings season is coming to a close and we’re looking back at what happened at four of our favorite med-tech companies. Inogen and Abiomed both tanked followed their earnings release while ShockWave Medical and Guardant Health both soared. Has the thesis long-term thesis for owning these stocks changed following their second-quarter results?
Booking,com and Expedia both have pretty similar business models. At their core, both companies sell travel bookings -- hotels, airfares, and rental cars primarily -- and they do so in a variety of different ways. Each company collects a fee for each booking it completes, acting as a middleman. That’s a strong business which requires no inventory but it’s also a model that comes with the risk of partners creating stronger direct relationships with their customers.
Thanks to a scathing report from Madoff whistleblower Harry Markopolis, General Electric (NYSE: GE) shares plunged 11% in a single day. Is this just market noise or something more? Plus, Federal Reserve Chair Jay Powell is set to deliver much-anticipated remarks on Thursday, and investors hope he gets aboard the rate-cutting train. And as always, host Jason Moser and Fool.com contributor Matt Frankel, CFP share the stocks on the top of their watch lists this week. All of this and more on this week’s Industry Focus: Financials show.
Co-working and co-living innovator WeWork has filed its prospectus in preparation for an IPO later in 2019. We dig into the numbers, explain why the business isn't really a tech company, and walk through the struggles the company will likely have in becoming profitable.
The history of the car is a story of how a new technology reshapes society, becomes part of its cultural identity, and is intertwined with a nation’s infrastructure. That history has shaped the world into which driverless vehicles may soon enter. Dan Albert, car critic at N+1 magazine and author of the new bookAre We There Yet: The American Automobile Past, Present, and Driverless, joins the podcast to discuss the history and cultural impact of the American car and where it may be headed as we transition toward a more electric, driverless future.
The FDA is investigating Novartis' subsidiary AveXis because AveXis may have manipulated data on Zolgensma, a gene therapy with a sky-high price tag and blockbuster potential. Here's what could happen next. Also, Exact Sciences goes all in on cancer diagnostics. Why the Cologuard-maker is spending $2.7 billion in a push deeper into genetic testing.
JC Penny is reportedly in talks to make some adjustments to its debt obligations -- we break down why even restructured financing isn't enough to right the ship for the struggling retailer and why a reverse stock split could be on the horizon. Then we hit some news items from Nike that hint at where the retail and apparel industries are going.
We're back with another _________ of __________ type business, this time we're talking about the Amazon of Africa, Jumia. The first African tech company to list on the NYSE shined in the weeks after its debut, but shares have come back down to IPO price as the dust has settled and some have warned of potential issues with the business. Should investors be eyeing this MercadoLibre wannabe?
Tesla is the most divisive company on the stock market, and it’s not close. Like most highly polarized topics, the truth is probably somewhere in the middle. To bridge that gap, Motley Fool Contributor Brian Feroldi, who is long Tesla shares, joins Industry Focus Host Nick Sciple, who is short Tesla via put options, to break down the facts surrounding the company and the reasoning behind their positions. We hope this discussion helps listeners form their own, independent conclusions about the stock.
The U.S. spends more than $24 billion each year on medical devices that help treat respiratory diseases, which is an enormous market opportunity. In this episode of Industry Focus: Healthcare, host Shannon Jones is joined by Fool.com contributor Brian Feroldi to talk about three innovative medical device companies — Inogen, Resmed, and Inspire Medical -- that are all major players in this growing industry and they share their opinion on whether or not these deserve a spot in your portfolio.
Get more great information on becoming a better investor -- free and straight to your inbox!
By submitting your email address, you consent to us keeping you informed about updates to our website and about other products and services that we think might interest you. You can unsubscribe at any time. Please read our Privacy Statement and Terms & Conditions.